Thyroid cancer is typically diagnosed through a combination of a physical exam, ultrasound imaging, and a needle biopsy that samples cells from a suspicious nodule. Most thyroid cancers are found after a nodule is detected, either during a routine checkup or on imaging done for another reason. The path from discovery to diagnosis usually takes a few weeks and involves progressively more detailed tests.
The Physical Exam
The first step is a neck examination. Your doctor will ask you to swallow, sometimes with a sip of water, while feeling the front of your neck. Swallowing lifts the thyroid gland, making it easier to detect asymmetry or lumps. A single nodule raises more suspicion for cancer than general enlargement, which is more commonly linked to conditions like Hashimoto’s thyroiditis or goiter.
That said, the physical exam has real limitations. As physicians at Stanford have noted, clinicians’ fingers are often positioned too far to the side of the neck to feel the gland’s true contours. Many thyroid nodules are too small to detect by touch alone, which is why imaging plays a much bigger role in diagnosis.
Ultrasound Imaging
A thyroid ultrasound is the most important imaging tool for evaluating a nodule. It’s painless, takes about 15 to 20 minutes, and uses sound waves to create a detailed picture of the thyroid and surrounding structures. The radiologist examines five key features of each nodule: its composition (solid vs. fluid-filled), its brightness compared to surrounding tissue, the sharpness of its edges, its shape, and whether it contains tiny bright spots called calcifications.
Each feature gets a point score under a system called TI-RADS, developed by the American College of Radiology. The total score places the nodule into a risk category ranging from benign (very low concern) to highly suspicious. This score, combined with the nodule’s size, determines whether a biopsy is recommended. Nodules that are completely fluid-filled or very small with no worrisome features can often just be monitored over time.
Fine Needle Aspiration Biopsy
If a nodule looks suspicious on ultrasound, the next step is a fine needle aspiration (FNA) biopsy. This is the test that can actually confirm or rule out cancer. You lie on your back with your head tipped slightly backward and a pillow under your shoulders to expose the neck. After cleaning the skin and sometimes applying a local anesthetic, the doctor inserts a very thin needle into the nodule using ultrasound guidance to place it precisely.
The needle withdraws a small sample of cells. Each pass takes only a few seconds, and the doctor typically repeats this two to six times, targeting different parts of the nodule with a fresh needle each time. If the nodule contains fluid, a syringe may be used to drain it. The entire procedure usually takes less than 30 minutes.
Most people tolerate FNA well. You can generally continue your regular medications beforehand, though blood thinners often need to be stopped a few days in advance. Afterward, mild soreness at the biopsy site is common and responds to over-the-counter pain relievers and ice. Most people return to normal activities the same day.
How Accurate Is the Biopsy?
FNA is highly reliable, with a specificity around 96.5%, meaning it rarely labels a benign nodule as cancerous. Its sensitivity sits around 85%, so it correctly identifies most cancers but does miss some. The false negative rate, where a cancer is present but the biopsy comes back normal, increases significantly with nodule size. For nodules under 1 cm, the false negative rate is about 3.4%. For nodules between 2 and 3 cm, it rises to around 16%. For nodules 3 cm or larger, it jumps to roughly 46%. This is one reason larger nodules may need closer follow-up even after a reassuring biopsy result.
Understanding Biopsy Results
Biopsy cells are examined under a microscope and classified using a six-category system called the Bethesda System. Each category carries a different estimated risk of cancer and leads to a different next step:
- Nondiagnostic: The sample didn’t contain enough cells to evaluate. A repeat biopsy is usually recommended.
- Benign: No signs of cancer. Routine monitoring with periodic ultrasound is typically all that’s needed.
- Atypia of undetermined significance: Some cells look unusual, but not clearly cancerous. This is the “gray zone” that often leads to molecular testing or a repeat biopsy.
- Follicular neoplasm: The cell pattern suggests a growth that could be benign or cancerous. Surgery to remove part of the thyroid is often recommended to get a definitive answer.
- Suspicious for malignancy: The cells strongly suggest cancer but aren’t conclusive. Surgery is typically the next step.
- Malignant: Cancer cells are clearly identified. Treatment planning begins.
Molecular Testing for Indeterminate Results
When a biopsy falls into one of the middle categories, particularly atypia of undetermined significance or follicular neoplasm, molecular testing can help clarify the picture. These tests look for specific gene mutations in the biopsy sample that are strongly associated with thyroid cancer. The three most important are BRAF, RET/PTC, and RAS.
Finding one of these mutations increases the likelihood that the nodule is cancerous and may push the recommendation toward surgery. Conversely, if no mutations are found, the risk of cancer drops substantially, and some patients can avoid an operation they might not need. Molecular testing doesn’t replace the biopsy but adds a layer of precision when the cell analysis alone isn’t clear-cut.
Blood Tests
Blood tests play a supporting role in thyroid cancer diagnosis. A TSH level is usually one of the first tests ordered. While it doesn’t detect cancer directly, an abnormally low TSH can suggest a nodule is overproducing thyroid hormone, which makes cancer less likely. An elevated TSH, on the other hand, is associated with a slightly higher cancer risk in nodules.
For one specific type of thyroid cancer, medullary thyroid cancer, a blood test for calcitonin can be directly diagnostic. Medullary cancer develops in cells that produce calcitonin, so elevated levels point strongly toward this diagnosis. The higher the calcitonin level, the more likely medullary thyroid cancer is present. In some cases, a stimulation version of the test is used: a substance is injected that should trigger calcitonin release, and a sharp spike in levels suggests medullary cancer or a precancerous condition called C-cell hyperplasia. However, a normal calcitonin level doesn’t completely rule out medullary cancer, since not all cases produce elevated levels.
Staging After Diagnosis
Once thyroid cancer is confirmed, it’s staged to determine how far it has spread. Staging uses the TNM system, which evaluates three things: the size and local extent of the tumor (T), whether cancer has reached nearby lymph nodes (N), and whether it has spread to distant organs (M).
Tumor size categories range from T1 (2 cm or smaller, still contained within the thyroid) through T4 (any size, but growing into surrounding structures like the windpipe, voice box, esophagus, spine, or major blood vessels). Lymph node involvement is classified as N0 (no spread) or N1, with N1 further divided based on whether affected nodes are immediately around the thyroid or farther away in the neck. Distant metastasis is either absent (M0) or present (M1), with the lungs and bones being the most common distant sites.
One important detail: staging for the most common thyroid cancers (papillary and follicular) also factors in your age. Patients under 55 are grouped differently and generally assigned a lower overall stage, reflecting the excellent prognosis these cancers carry in younger people. This means two patients with identical tumors can receive different stage designations based on age alone.